Durham
Durham pharma firm Biocryst pulls plug on COVID-19 efforts
by Frank Vinluan, NCBiotech writer — December 29, 2020 .
DURHAM – BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. But SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them.
The Durham company has reported early stage clinical trial results showing that treatment with the experimental antiviral offered COVID-19 patientsno benefitcompared to a placebo. The study wasn’t designed to demonstrate clinical efficacy, and small Phase 1 clinical trials typically enroll healthy volunteers to assess a drug’s safety before testing the drug on sick patients. Galidesivir achieved the safety measure with no serious problems associated with the drug.
Galidesivir is a broad-spectrum antiviral designed to block RNA polymerase, a key viral enzyme. Prior to the current pandemic, BioCryst was developing its intravenously administered drug as a potential treatment for serious viral pathogens including Ebola, Marburg, Yellow Fever, and Zika. The company says its drug has also shown a broad spectrum of activity against more than 20 RNA viruses, including coronaviruses.
https://www.wraltechwire.com/2020/12/29/durham-pharma-firm-biocryst-pulls-plug-on-covid-19-efforts/
Durham=No Benefit